The North America Continuous Glucose Monitoring Device Market is expected to witness market growth of 11.6% CAGR during the forecast period (2020-2026).
Continuous glucose monitors (CGMs) contain subcutaneous sensors that track interstitial glucose levels every 1-5 minutes, offering alerts when glucose levels are too high or too low, or increase or fall rapidly. CGMs transmit to a receiver which is either a pager-like device or an insulin pump integral to it. Looking at the continuous glucose graph and the alarm response can help patients avoid severe hyperglycemia or hypoglycemia.
These systems, unlike conventional glucose monitors, allow for periodic monitoring of glucose levels, which is critically important for avoiding diabetic complications. In fact, GCMS research has set out a blueprint for the artificial/bionic pancreas that is much awaited, high-tech, closed-loop. Thus, the development of novel and technologically advanced CGMS is the primary focus of the manufacturing companies that monitor glucose devices. It offers a broad range of applications for all age cohorts, healthcare settings, and geographies. Thus, the market for continuous glucose monitoring devices provides lucrative opportunities for producers of CGMS and manufacturers of insulin pumps.
Several governments across the globe are introducing various diabetes treatment measures, allowing continuous glucose monitoring devices to be more widely adopted. Diabetes challenges the US population's health in many ways. The high prevalence and cost of diabetes are two reasons that have enforced the US government to control diabetes more effectively. In order to better control diabetes, the government is implementing a variety of actions addressing lifestyle and socioeconomic factors, screening and medical management, and public awareness campaigns.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study
Market Segmentation:
By Component
By End User
By Country
Companies Profiled:
Unique Offerings from the Publisher:
Continuous glucose monitors (CGMs) contain subcutaneous sensors that track interstitial glucose levels every 1-5 minutes, offering alerts when glucose levels are too high or too low, or increase or fall rapidly. CGMs transmit to a receiver which is either a pager-like device or an insulin pump integral to it. Looking at the continuous glucose graph and the alarm response can help patients avoid severe hyperglycemia or hypoglycemia.
These systems, unlike conventional glucose monitors, allow for periodic monitoring of glucose levels, which is critically important for avoiding diabetic complications. In fact, GCMS research has set out a blueprint for the artificial/bionic pancreas that is much awaited, high-tech, closed-loop. Thus, the development of novel and technologically advanced CGMS is the primary focus of the manufacturing companies that monitor glucose devices. It offers a broad range of applications for all age cohorts, healthcare settings, and geographies. Thus, the market for continuous glucose monitoring devices provides lucrative opportunities for producers of CGMS and manufacturers of insulin pumps.
Several governments across the globe are introducing various diabetes treatment measures, allowing continuous glucose monitoring devices to be more widely adopted. Diabetes challenges the US population's health in many ways. The high prevalence and cost of diabetes are two reasons that have enforced the US government to control diabetes more effectively. In order to better control diabetes, the government is implementing a variety of actions addressing lifestyle and socioeconomic factors, screening and medical management, and public awareness campaigns.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study
Market Segmentation:
By Component
- Sensors
- Transmitters and
- Receivers
By End User
- Hospitals
- Homecare Settings and
- Other End Users
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled:
- Abbott Laboratories
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- DexCom, Inc.
- Ypsomed AG
- Senseonics Holdings, Inc.
- GlySens, Incorporated
- A. Menarini Diagnostics Ltd. (The Menarini Group)
- Echo Therapeutics, Inc.
- Johnson and Johnson
Unique Offerings from the Publisher:
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Continuous Glucose Monitoring Device Market by Component
Chapter 4. North America Continuous Glucose Monitoring Device Market by End-user
Chapter 5. North America Continuous Glucose Monitoring Device Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- DexCom, Inc.
- Ypsomed AG
- Senseonics Holdings, Inc.
- GlySens, Incorporated
- A. Menarini Diagnostics Ltd. (The Menarini Group)
- Echo Therapeutics, Inc.
- Johnson and Johnson
Methodology
LOADING...
